117 related articles for article (PubMed ID: 24206045)
1. Mutations in the RNA splicing machinery genes in myelofibrotic transformation of essential thrombocythaemia and polycythaemia vera.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Camacho L; Pairet S; Fernández-Rodríguez C; Serrano S; Bellosillo B
Br J Haematol; 2014 Feb; 164(4):605-7. PubMed ID: 24206045
[No Abstract] [Full Text] [Related]
2. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
3. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
Alvarez-Larrán A; Senín A; Fernández-Rodríguez C; Pereira A; Arellano-Rodrigo E; Gómez M; Ferrer-Marin F; Martínez-López J; Camacho L; Colomer D; Angona A; Navarro B; Cervantes F; Besses C; Bellosillo B; Hernández-Boluda JC
Br J Haematol; 2017 Sep; 178(5):764-771. PubMed ID: 28542718
[TBL] [Abstract][Full Text] [Related]
4. Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.
Tiong IS; Casolari DA; Nguyen T; Van Velzen MJ; Ambler K; D'Andrea RJ; Ross DM
Blood Cancer J; 2016 Aug; 6(8):e459. PubMed ID: 27540717
[No Abstract] [Full Text] [Related]
5. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
Tefferi A; Guglielmelli P; Lasho TL; Coltro G; Finke CM; Loscocco GG; Sordi B; Szuber N; Rotunno G; Pacilli A; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Vannucchi AM
Br J Haematol; 2020 Apr; 189(2):291-302. PubMed ID: 31945802
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
7. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Löfvenberg E; Wahlin A
Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
[TBL] [Abstract][Full Text] [Related]
8. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
[No Abstract] [Full Text] [Related]
9. Low incidence of familial occurrence of thrombocythaemia and/or thrombocytosis.
Randi ML; Fabris F; Visentin I; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):695-9. PubMed ID: 2465250
[TBL] [Abstract][Full Text] [Related]
10. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.
Soriano G; Heaney M
Curr Opin Hematol; 2013 Mar; 20(2):169-75. PubMed ID: 23298878
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Andersen CL; McMullin MF; Ejerblad E; Zweegman S; Harrison C; Fernandes S; Bareford D; Knapper S; Samuelsson J; Löfvenberg E; Linder O; Andreasson B; Ahlstrand E; Jensen MK; Bjerrum OW; Vestergaard H; Larsen H; Klausen TW; Mourits-Andersen T; Hasselbalch HC
Br J Haematol; 2013 Aug; 162(4):498-508. PubMed ID: 23758082
[TBL] [Abstract][Full Text] [Related]
13. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
14. Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombocythemia.
Borze I; Mustjoki S; Juvonen E; Knuutila S
Haematologica; 2008 Jul; 93(7):1098-100. PubMed ID: 18591627
[No Abstract] [Full Text] [Related]
15. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance.
Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Res; 2012 Nov; 36(11):1387-92. PubMed ID: 22877729
[TBL] [Abstract][Full Text] [Related]
16. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.
Passamonti F; Pietra D; Rumi E; Arcaini L; Della Porta MG; Malcovati L; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2005 May; 19(5):888-9. PubMed ID: 15744342
[No Abstract] [Full Text] [Related]
17. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study.
Gisslinger H; Müllner M; Pabinger I; Heis-Vahidi-Fard N; Gisslinger B; Brichta A; Bachleitner-Hofmann T; Mannhalter C
Haematologica; 2005 Mar; 90(3):408-10. PubMed ID: 15749677
[TBL] [Abstract][Full Text] [Related]
18. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
19. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hasselbalch HC
Leuk Res; 2013 Feb; 37(2):214-20. PubMed ID: 23174192
[TBL] [Abstract][Full Text] [Related]
20. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
